Nanoparticle-enhanced PD-1/PD-L1 targeted combination therapy for triple negative breast cancer

被引:1
作者
Linde, Caroline [1 ]
Chien, Yu-Ting [1 ]
Chen, Zhiqian [1 ]
Mu, Qingxin [1 ]
机构
[1] Univ Washington, Dept Pharmaceut, Seattle, WA 98195 USA
来源
FRONTIERS IN ONCOLOGY | 2024年 / 14卷
基金
美国国家卫生研究院;
关键词
nanoparticles; triple negative breast cancer; PD-1/PD-L1; pathway; combination therapy; tumor microenvironment; CHEMOTHERAPY; PHARMACOKINETICS; IMMUNOTHERAPY;
D O I
10.3389/fonc.2024.1393492
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Breast cancer with triple-negative subtype (TNBC) presents significant challenges with limited treatment options and a poorer prognosis than others. While PD-1/PD-L1 checkpoint inhibitors have shown promise, their efficacy in TNBC remains constrained. In recent years, nanoparticle (NP) technologies offer a novel approach to enhance cancer therapy by optimizing the tumor microenvironment and augmenting chemo- and immunotherapy effects in various preclinical and clinical settings. This review discusses recent investigations in NP strategies for improving PD-1/PD-L1 blockade-based combination therapy for TNBC. Those include single or multi-therapeutic NPs designed to enhance immunogenicity of the tumor, induce immunogenic cell death, and target immunosuppressive elements within the tumor microenvironment. The investigations also include NPs co-loaded with PD-L1 inhibitors and other therapeutic agents, leveraging targeted delivery and synergistic effects to maximize efficacy while minimizing systemic toxicity. Overall, NP approaches represent a promising avenue for enhancing PD-1/PD-L1 checkpoint blockade-based combination therapy in TNBC and encourage further developmental studies.
引用
收藏
页数:7
相关论文
共 50 条
  • [31] Targeting PD-1/PD-L1 in cancer immunotherapy: An effective strategy for treatment of triple-negative breast cancer (TNBC) patients
    Kumar, Sunny
    Chatterjee, Mouli
    Ghosh, Pratyasha
    Ganguly, Kirat K.
    Basu, Malini
    Ghosh, Mrinal K.
    [J]. GENES & DISEASES, 2023, 10 (04) : 1318 - 1350
  • [32] Intratumoral nanofluidic system enhanced tumor biodistribution of PD-L1 antibody in triple-negative breast cancer
    Liu, Hsuan-Chen
    Capuani, Simone
    Badachhape, Andrew A.
    Di Trani, Nicola
    Gonzalez, Daniel Davila
    Pol, Robin S. Vander
    Viswanath, Dixita I.
    Saunders, Shani
    Hernandez, Nathanael
    Ghaghada, Ketan B.
    Chen, Shu-Hsia
    Nance, Elizabeth
    Annapragada, Ananth V.
    Chua, Corrine Ying Xuan
    Grattoni, Alessandro
    [J]. BIOENGINEERING & TRANSLATIONAL MEDICINE, 2023, 8 (06)
  • [33] PD-1/PD-L1 immune checkpoint inhibitors in metastatic triple-negative breast cancer: a systematic review and meta-analysis
    Yu, Yinan
    Jin, Xueying
    Zhu, Xiaoling
    Xu, Yan
    Si, Wei
    Zhao, Jianguo
    [J]. FRONTIERS IN IMMUNOLOGY, 2023, 14
  • [34] Combined immunotherapy for metastatic triple-negative breast cancer based on PD-1/PD-L1 immune checkpoint blocking
    He, Rui
    Yuan, Xing
    Chen, Zeran
    Zheng, Yongfeng
    [J]. INTERNATIONAL IMMUNOPHARMACOLOGY, 2022, 113
  • [35] Efficacy and safety of PD-1 and PD-L1 inhibitors combined with chemotherapy in randomized clinical trials among triple-negative breast cancer
    Qi, Yihang
    Zhang, Wenxiang
    Jiang, Ray
    Xu, Olivia
    Kong, Xiangyi
    Zhang, Lin
    Fang, Yi
    Wang, Jingping
    Wang, Jing
    [J]. FRONTIERS IN PHARMACOLOGY, 2022, 13
  • [36] Targeting PD-1 or PD-L1 in Metastatic Kidney Cancer: Combination Therapy in the First-Line Setting
    Aggen, David H.
    Drake, Charles G.
    Rini, Brian I.
    [J]. CLINICAL CANCER RESEARCH, 2020, 26 (09) : 2087 - 2095
  • [37] The association of genomic lesions and PD-1/PD-L1 expression in resected triple-negative breast cancers
    Michael T. Barrett
    Elizabeth Lenkiewicz
    Smriti Malasi
    Anamika Basu
    Jennifer Holmes Yearley
    Lakshmanan Annamalai
    Ann E. McCullough
    Heidi E. Kosiorek
    Pooja Narang
    Melissa A. Wilson Sayres
    Meixuan Chen
    Karen S. Anderson
    Barbara A. Pockaj
    [J]. Breast Cancer Research, 20
  • [38] The association of genomic lesions and PD-1/PD-L1 expression in resected triple-negative breast cancers
    Barrett, Michael T.
    Lenkiewicz, Elizabeth
    Malasi, Smriti
    Basu, Anamika
    Yearley, Jennifer Holmes
    Annamalai, Lakshmanan
    McCullough, Ann E.
    Kosiorek, Heidi E.
    Narang, Pooja
    Sayres, Melissa A. Wilson
    Chen, Meixuan
    Anderson, Karen S.
    Pockaj, Barbara A.
    [J]. BREAST CANCER RESEARCH, 2018, 20
  • [39] Molecular and Immune Correlates of PDCD1 (PD-1), PD-L1 (CD274), and PD-L2 (PDCD1LG2) DNA Methylation in Triple Negative Breast Cancer
    Ralser, Damian J.
    Kluemper, Niklas
    Gevensleben, Heidrun
    Zarbl, Romina
    Kaiser, Christina
    Landsberg, Jennifer
    Hoelzel, Michael
    Strieth, Sebastian
    Faridi, Andree
    Abramian, Alina
    Dietrich, Dimo
    [J]. JOURNAL OF IMMUNOTHERAPY, 2021, 44 (08) : 319 - 324
  • [40] Blockade of CCL2 expression overcomes intrinsic PD-1/PD-L1 inhibitor-resistance in transglutaminase 2-induced PD-L1 positive triple negative breast cancer
    Choi, Junyoung
    Lee, Hee Jin
    Yoon, Shinkyo
    Ryu, Hyun-Min
    Lee, Eunjin
    Jo, Yujin
    Seo, Seyoung
    Kim, Deokhoon
    Lee, Chang Hoon
    Kim, Wanlim
    Ha, Joo Young
    Kim, Soo-Youl
    Gong, Gyungyub
    Jung, Kyung Hae
    Park, Sook Ryun
    Kim, Sang-We
    Park, Kang-Seo
    Lee, Dae Ho
    [J]. AMERICAN JOURNAL OF CANCER RESEARCH, 2020, 10 (09): : 2878 - +